Cited by 4,148Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancer

The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.

Innate and adaptive immune cells in the tumor microenvironment

Open access

Gajewski, Thomas F, Schreiber, Hans, Fu, Yang-Xin·2013·Nature Immunology

Open this paper in CoChat — free account

Abstract

Most tumor cells express antigens that can mediate recognition by host CD8(+) T cells. Cancers that are detected clinically must have evaded antitumor immune responses to grow progressively. Recent work has suggested two broad categories of tumor escape based on cellular and molecular characteristics of the tumor microenvironment. One major subset shows a T cell-inflamed phenotype consisting of infiltrating T cells, a broad chemokine profile and a type I interferon signature indicative of innate immune activation. These tumors appear to resist immune attack through the dominant inhibitory effects of immune system-suppressive pathways. The other major phenotype lacks this T cell-inflamed phenotype and appears to resist immune attack through immune system exclusion or ignorance. These two major phenotypes of tumor microenvironment may require distinct immunotherapeutic interventions for maximal therapeutic effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ni.2703

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137
Retracted
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397

Flagged first, then by citations

Show all 149 references

Research works printed but not linked: 1

Spranger, S. et al. Upregulation of PD-L1, IDO and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. (in the press).

Sorted by citations

Items 401–500 of 1,004

Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment
Tanaka, M., & Siemann, D. W. (2020) · Cancers · doi:10.3390/cancers12071850 · Cited by 148
Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress
Hasmim, M., Messai, Y., Ziani, L., Thiery, J., Bouhris, J.-H., Noman, M. Z., & Chouaı̈b, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00482 · Cited by 148
CD4-Transgenic Zebrafish Reveal Tissue-Resident Th2- and Regulatory T Cell–like Populations and Diverse Mononuclear Phagocytes
Dee, C., Nagaraju, R. T., Athanasiadis, E. I., Gray, C., del Ama, L. F., Johnston, S. A., Secombes, C. J., Cvejic, A., & Hurlstone, A. F. L. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600959 · Cited by 143
Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer
Zhang, Y., Chen, H., Mo, H., Zhao, N., Sun, X., Liu, B., Gao, R., Xu, B., Zhang, Z., Liu, Z., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.007 · Cited by 153
AND-gate contrast agents for enhanced fluorescence-guided surgery
Widen, J. C., Tholen, M., Yim, J. J., Antaris, A., Casey, K. M., Rogalla, S., Klaassen, A., Sorger, J., & Bogyo, M. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00616-6 · Cited by 142
CD8 + /FOXP3 + -ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study
Fritzsching, B., Fellenberg, J., Moskovszky, L. E., Sápi, Z., Krenács, T., Machado, I., Poeschl, J., Lehner, B., Szendrői, M., Bosch, A. L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.990800 · Cited by 140
Biomarkers for Immunotherapy: Current Developments and Challenges
Spencer, K. R., Wang, J., Silk, A. W., Ganesan, S., Kaufman, H. L., & Mehnert, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_160766 · Cited by 148
Targeted drug delivery to melanoma
Liu, Q., Das, M., Liu, Y., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.016 · Cited by 139
Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
Kowalsky, S. J., Liu, Z., Feist, M., Berkey, S. E., Ma, C., Ravindranathan, R., Dai, E., Roy, E. J., Guo, Z. S., & Bartlett, D. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.013 · Cited by 142
Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
Gameiro, S. F., Ghasemi, F., Barrett, J. W., Koropatnick, J. D., Nichols, A. C., Mymryk, J. S., & Vareki, S. M. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1498439 · Cited by 142
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
Russell, L., Peng, K. W., Russell, S. J., & Díaz, R. M. (2019) · BioDrugs · doi:10.1007/s40259-019-00367-0 · Cited by 146
KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation
Boudreau, J. E., Giglio, F., Gooley, T. A., Stevenson, P. A., Luduec, J.-B. L., Shaffer, B. C., Rajalingam, R., Hou, L., Hurley, C. K., Noreen, H. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7059 · Cited by 138
The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform
Schachtschneider, K. M., Schwind, R. M., Newson, J. L., Kinachtchouk, N., Rizko, M., Mendoza-Elias, N., Grippo, P. J., Principe, D. R., Park, A. J., Overgaard, N. H., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00190 · Cited by 145
Astrocytic trans-Differentiation Completes a Multicellular Paracrine Feedback Loop Required for Medulloblastoma Tumor Growth
Yao, M., Ventura, P. B., Jiang, Y., Rodriguez, F. J., Wang, L., Perry, J. S. A., Yang, Y., Wahl, K., Crittenden, R. B., Bennett, M. L., et al. (2020) · Cell · doi:10.1016/j.cell.2019.12.024 · Cited by 133
Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis
Yu, X., Zhang, Z., Wang, Z., Wu, P., Qiu, F., & Huang, J. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1391-y · Cited by 137
Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy
Lin, A., & Yan, W. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00083 · Cited by 137
Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms
Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136
Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites
Dong, X., Chu, D., & Wang, Z. (2017) · Theranostics · doi:10.7150/thno.18069 · Cited by 137
Cancer Cell–Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti–PD-1 Therapy in Lung Adenocarcinoma
Johnson, A. M., Bullock, B., Neuwelt, A. J., Poczobutt, J. M., Kaspar, R. E., Li, H. Y., Kwak, J., Hopp, K., Weiser-Evans, M. C. M., Heasley, L. E., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900778 · Cited by 134
Combination of Radiotherapy and Immune Checkpoint Inhibitors
Pilones, K. A., Vanpouille‐Box, C., & Demaria, S. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.004 · Cited by 140
Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment
Cui, Y. R., & Guo, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111942 · Cited by 137
Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy
Hu, X., Wang, J., Chu, M., Liu, Y., Wang, Z. P., & Zhu, X. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.032 · Cited by 140
Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development
Kantono, M., & Guo, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01132 · Cited by 133
Immune checkpoint blockade therapy
Wieder, T., Eigentler, T., Brenner, E., & Röcken, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.042 · Cited by 134
Peptide‐Based Multifunctional Nanomaterials for Tumor Imaging and Therapy
Zhang, C., Wu, W. H., Li, R., Qiu, W., Zhuang, Z., Cheng, S., & Zhang, X. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201804492 · Cited by 136
Recent Progress in Magnetically Actuated Microrobots for Targeted Delivery of Therapeutic Agents
Choi, J., Hwang, J., Kim, J., & Choi, H. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001596 · Cited by 135
Engineering opportunities in cancer immunotherapy
Jeanbart, L., & Swartz, M. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508516112 · Cited by 133
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study
Planchard, D., Yokoi, T., McCleod, M., Fischer, J. R., Kim, Y., Ballas, M. S., Shi, K., & Soria, J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.003 · Cited by 130
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps
Beatty, G. L., & O’Hara, M. H. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.010 · Cited by 131
Cell spheroids: the new frontiers in in vitro models for cancer drug validation
Chatzinikolaidou, Μ. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.024 · Cited by 134
Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
Wirsdörfer, F., de Leve, S., & Jendrossek, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010024 · Cited by 133
TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti–PD-1 Therapy in Melanoma
Holtzhausen, A., Harris, W. P., Ubil, E., Hunter, D. M., Zhao, J., Zhang, Y., Zhang, D., Liu, Q., Wang, X., Graham, D. K., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0008 · Cited by 132
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Fan, Q., Chen, Z., Wang, C., & Liu, Z. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802540 · Cited by 129
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.024 · Cited by 135
Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling
Li, Z., Zhang, Y., Hong, W., Wang, B., Chen, Y., Yang, P., Zhou, J., Fan, J., Zeng, Z., & Du, S. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2119055 · Cited by 133
Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma
Oweida, A., Lennon, S., Calame, D. J., Korpela, S. P., Bhatia, S., Sharma, J., Graham, C., Binder, D. C., Serkova, N. J., Raben, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356153 · Cited by 130
Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment
Darragh, L. B., Oweida, A., & Karam, S. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03154 · Cited by 133
PD‐1/PD‐L1‐dependent immune response in colorectal cancer
Payandeh, Z., Khalili, S., Somi, M. H., Mard‐Soltani, M., Baghbanzadeh, A., Hajiasgharzadeh, K., Samadi, N., & Baradaran, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29494 · Cited by 129
Top Notch Targeting Strategies in Cancer: A Detailed Overview of Recent Insights and Current Perspectives
Moore, G., Annett, S., McClements, L., & Robson, T. (2020) · Cells · doi:10.3390/cells9061503 · Cited by 129
Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation
Liu, Q., Hodge, J., Wang, J., Wang, Y., Wang, L., Singh, U. P., Li, Y., Yao, Y., Wang, D., Ai, W., et al. (2020) · Theranostics · doi:10.7150/thno.45395 · Cited by 129
Myeloid-Derived Cells in Tumors: Effects of Radiation
Vatner, R. E., & Formenti, S. C. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.008 · Cited by 131
Mast cells as protectors of health
Dudeck, A., Köberle, M., Goldmann, O., Meyer, N., Dudeck, J., Lemmens, S., Rohde, M., Roldán, N. G., Dietze‐Schwonberg, K., Orinska, Z., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.054 · Cited by 134
Molecular pathogenic pathways in extranodal NK/T cell lymphoma
Mel, S. D., Hue, S. S., Jeyasekharan, A. D. D., Chng, W. J., & Ng, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0716-7 · Cited by 127
Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma
Yi, M., Li, A., Zhou, L., Chu, Q., Luo, S., & Wu, K. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02817-z · Cited by 127
Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease
Markowitz, J., Brooks, T., Duggan, M. C., Paul, B. K., Pan, X. J., Wei, L., Abrams, Z. B., Luedke, E. A., Lesinski, G. B., Mundy-Bosse, B. L., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1618-8 · Cited by 131
BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining
Bi, K., Wei, X.-G., Qin, X., & Li, B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00424 · Cited by 127
New Approaches on Cancer ImmunotherapyPreprint
Cha, J., Chan, L.-C., Song, M. S., & Hung, M. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036863 · Cited by 130
Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma
Sivakumar, S., Lucas, F. A. S., McDowell, T. L., Lang, W., Li, X., Fujimoto, J., Zhang, J. J., Futreal, P. A., Fukuoka, J., Yatabe, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1605 · Cited by 123
Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells
Poggi, A. D., Musso, A., Dapino, I., & Zocchi, M. R. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.03.001 · Cited by 126
The Prognostic and Therapeutic Value of PD-L1 in Glioma
Chen, R. Q., Liu, F., Qiu, X. Y., & Chen, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01503 · Cited by 123
The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles
Hu, Y., Liu, Y., Zong, L., Zhang, W., Liu, R., Xing, Q., Liu, Z., Yan, Q., Li, W., Lei, H., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06382-y · Cited by 140
Tumor-Infiltrating γδ T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programing in the Tumor Microenvironment
Presti, E. L., Dieli, F., & Meraviglia, S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00607 · Cited by 124
Wnt/β-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy
Wu, X., Que, H., Li, Q., & Wei, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02363-1 · Cited by 155
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 122
Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion
Wang, Z., Li, B., Li, S., Lin, W., Wang, Z., Wang, S., Chen, W., Shi, W., Chen, T., Zhou, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34064-4 · Cited by 123
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression.
Koelwyn, G. J., Wennerberg, E., Demaria, S., & Jones, L. W. (2015) · PubMed · Cited by 130
Developing a Bright NIR‐II Fluorophore with Fast Renal Excretion and Its Application in Molecular Imaging of Immune Checkpoint PD‐L1
Wan, H., Ma, H., Zhu, S., Wang, F., Tian, Y., Ma, R., Yang, Q., Hu, Z., Zhu, T., Wang, W., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201804956 · Cited by 120
Tumor-Associated Neutrophils and Macrophages—Heterogenous but Not Chaotic
Wu, L., & Zhang, X. H.-F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.553967 · Cited by 124
Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy
Meng, Q., Zhao, Y., Dong, C., Liu, L., Pan, Y., Lai, J., Liu, Z., Yu, G., Chen, X. S., & Rao, L. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202108342 · Cited by 120
Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens
DeFalco, J., Harbell, M. G., Manning-Bog, A., Baía, G. S., Scholz, A., Millare, B., Sumi, M., Zhang, D., Chu, F., Dowd, C., et al. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.10.002 · Cited by 119
Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells
Sethumadhavan, S., Silva, M., Philbrook, P., Nguyen, T., Hatfield, S. M., Ohta, A., & Sitkovsky, M. V. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187314 · Cited by 119
Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Gartrell, R. D., Marks, D. K., Hart, T. D., Li, G., Davari, D. R., Wu, A., Blake, Z., Lu, Y., Askin, K. N., Monod, A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0360 · Cited by 119
Self-citation
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell–inflamed phenotype
Godfrey, J. K., Tumuluru, S., Bao, R., Leukam, M. J., Venkataraman, G., Phillip, J., Fitzpatrick, C. A., McElherne, J., MacNabb, B. W., Orlowski, R. J., et al. (2019) · Blood · doi:10.1182/blood-2018-10-879015 · Cited by 117
Controlled Delivery of Nitric Oxide for Cancer Therapy
Alimoradi, H., Greish, K. F., Gamble, A. B., & Giles, G. I. (2019) · Pharmaceutical Nanotechnology · doi:10.2174/2211738507666190429111306 · Cited by 120
Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function
Fernández, J. P., Luddy, K. A., Harmon, C., & O’Farrelly, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174131 · Cited by 119
The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Linxweiler, M., Kuo, F., Katabi, N., Lee, M., Nadeem, Z., Dalin, M. G., Makarov, V., Chowell, D., Doğan, S., Ganly, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3758 · Cited by 116
Colibactin‐positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer
Lopès, A., Billard, E., Casse, A. H., Villéger, R., Véziant, J., Roche, G., Carrier, G., Sauvanet, P., Briat, A., Pagès, F., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32920 · Cited by 125
Anti–PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells
Rao, G., Latha, K., Ott, M., Sabbagh, A., Marisetty, A., Ling, X., Zamler, D. B., Doucette, T. A., Yang, Y., Kong, L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4110 · Cited by 117
Turning cold into hot: emerging strategies to fire up the tumor microenvironment
Ma, K., Wang, L., Li, W., Tang, T., Ma, B., Zhang, L., & Zhang, L. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.11.011 · Cited by 125
Cutaneous melanoma
Tasdogan, A., Sullivan, R. J., Katalinic, A., Lebbé, C., Whitaker, D., Puig, S., van de Poll-Franse, L. V., Massi, D., & Schadendorf, D. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00603-8 · Cited by 143
Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway
Moore, G., & Pidgeon, G. P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020236 · Cited by 119
Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy
Zhang, Q., Zhu, B., & Li, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00071 · Cited by 121
Exploring Metabolic Configurations of Single Cells within Complex Tissue Microenvironments
Miller, A., Nagy, C., Knapp, B., Laengle, J., Ponweiser, E., Gröger, M., Starkl, P. M., Bergmann, M. M., Wagner, O. F., & Haschemi, A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.014 · Cited by 123
The Complex Interplay between Chronic Inflammation, the Microbiome, and Cancer: Understanding Disease Progression and What We Can Do to Prevent It
Armstrong, H., Bording‐Jorgensen, M., Dijk, S., & Wine, E. (2018) · Cancers · doi:10.3390/cancers10030083 · Cited by 122
Oncolytic viruses: overcoming translational challenges
Martínez‐Quintanilla, J., Seah, I. Y. J., Chua, M. M. J., & Shah, K. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122287 · Cited by 122
Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration
Chun, H.-J. E., Johann, P. D., Milne, K., Zapatka, M., Büllesbach, A., Ishaque, N., Iskar, M., Erkek, S., Wei, L. L., Tessier‐Cloutier, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.013 · Cited by 117
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE
Schobert, I. T., Savic, L. J., Chapiro, J., Bousabarah, K., Chen, E. M., Gaupp, F. M. L., Tefera, J., Nezami, N., Lin, M., Pollak, J. S., et al. (2020) · European Radiology · doi:10.1007/s00330-020-06931-5 · Cited by 118
Targeting Innate Immunity in Cancer Therapy
Rameshbabu, S., Labadie, B. W., Argulian, A., & Patnaik, A. (2021) · Vaccines · doi:10.3390/vaccines9020138 · Cited by 121
In situ cancer vaccination using lipidoid nanoparticles
Chen, J., Qiu, M., Ye, Z., Li, Y., Li, Y., Glass, Z., Zhao, X., Yang, L., Chen, J., & Xu, Q. (2021) · Science Advances · doi:10.1126/sciadv.abf1244 · Cited by 118
YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy
Hu, J. M., Qiu, D., Yu, A., Hu, J., Deng, H., Li, H., Yi, Z., Chen, J., & Zu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.607224 · Cited by 115
Ginsenosides are active ingredients in Panax ginseng with immunomodulatory properties from cellular to organismal levels
You, L., Cha, S., Kim, M., & Cho, J. Y. (2021) · Journal of Ginseng Research · doi:10.1016/j.jgr.2021.12.007 · Cited by 122
CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma
Liu, J. Y., Li, F., Wang, L. P., Chen, X., Wang, D., Cao, L., Yü, P., Zhao, S., Li, B., Thorne, S. H., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.290 · Cited by 119
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 117
Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Rosenblatt, J. M., & Avigan, D. (2016) · Blood · doi:10.1182/blood-2016-08-731885 · Cited by 117
Prospects for combined use of oncolytic viruses and CAR T-cells
Ajina, A., & Maher, J. F. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0294-6 · Cited by 120
Role of Inflammatory Mediators, Macrophages, and Neutrophils in Glioma Maintenance and Progression: Mechanistic Understanding and Potential Therapeutic Applications
Basheer, A. S., Abas, F., Othman, I., & Naidu, R. (2021) · Cancers · doi:10.3390/cancers13164226 · Cited by 120
Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea
Cubillos-Zapata, C., Avendaño-Ortiz, J., Hernandez-Jimenez, E., Toledano, V., Casas-Martin, J., Varela-Serrano, A., Torres, M., Almendros, I., Casitas, R., Fernández-Navarro, I., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00833-2017 · Cited by 116
A comprehensive review of SHP2 and its role in cancer
Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119
Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy
Berger, G., Marloye, M., & Lawler, S. E. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.02.007 · Cited by 117
A Comprehensive Picture of Extracellular Vesicles and Their Contents. Molecular Transfer to Cancer Cells
Jurj, A. M., Zănoagă, O., Braicu, C., Lazar, V., Tomuleasa, C., Irimie, A., & Berindan‐Neagoe, I. (2020) · Cancers · doi:10.3390/cancers12020298 · Cited by 119
DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation
Huang, X., Williams, J. Z., Chang, R., Li, Z., Burnett, C. E., Hernández-López, R. A., Setiady, I., Gai, E., Patterson, D. M., Yu, W., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-00813-z · Cited by 111
Current Understanding of Flavonoids in Cancer Therapy and Prevention
Farhan, M., Rizvi, A., Aatif, M., & Ahmad, A. (2023) · Metabolites · doi:10.3390/metabo13040481 · Cited by 128
CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy
Liu, Z., Ravindranathan, R., Li, J., Kalinski, P., Guo, Z. S., & Bartlett, D. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1091554 · Cited by 113
The Process and Regulatory Components of Inflammation in Brain Oncogenesis
Mostofa, A., Punganuru, S. R., Madala, H. R., Al-Obaide, M., & Srivenugopal, K. S. (2017) · Biomolecules · doi:10.3390/biom7020034 · Cited by 121
The role of the hypoxia‐Nrp‐1 axis in the activation of M2‐like tumor‐associated macrophages in the tumor microenvironment of cervical cancer
Chen, X., Wu, S., Yan, R.-M., Fan, L., Yu, L., Zhang, Y., Wei, W., Zhou, C., Wu, X., Zhong, M., et al. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22936 · Cited by 115
IL-6 Activities in the Tumour Microenvironment. Part 1
Chonov, D. C., Ignatova, M., Ananiev, J. R., & Gulubova, M. V. (2019) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2019.589 · Cited by 120
Turning tumors from cold to inflamed to improve immunotherapy response
Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 118
Ferroptosis‐related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma
Lei, T., Hu, Q., Lei, P., & Hu, Y. (2021) · Cancer Science · doi:10.1111/cas.15131 · Cited by 114
Blueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 124
Conventional NK cells and tissue-resident ILC1s join forces to control liver metastasis
Ducimetière, L., Lucchiari, G., Litscher, G., Nater, M., Heeb, L., Núñez, N. G., Wyss, L., Bürri, D., Vermeer, M., Gschwend, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026271118 · Cited by 119

Authors: Gajewski, T. F., Schreiber, H., & Fu, Y.-X.
Affiliations: University of Chicago (US)
Corresponding author: Gajewski, Thomas F
ORCID: Schreiber, Hans
Fu, Yang-Xin
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2013-09-18
Volume: 14
Issue: 10
Pages: 1014-1022
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni.2703
PMC: PMC4118725
OpenAlex: W2042699075
Cited by: 4,148
References: 149
Citations by year: 2026: 187 · 2025: 310 · 2024: 432 · 2023: 486 · 2022: 443 · 2021: 522 · 2020: 372 · 2019: 315 · 2018: 290 · 2017: 290 · 2016: 240 · 2015: 162 · 2014: 82 · 2013: 1
FWCI: 17.11
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA161005, R01CA127475, R01CA118153)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords: tumor microenvironment, tumor immune evasion, innate immunity, adaptive immunity, CD8+ T cells, immune exclusion, type I interferon signature, chemokine profile, immune checkpoint blockade, cancer immunotherapy
MeSH terms: Animals, Dendritic Cells, Humans, Immunity, Innate, Lymphocyte Activation, Neoplasms, T-Lymphocyte Subsets, Stromal Cells, Adaptive Immunity, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Innate and adaptive immune cells in the tumor microenvironment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks